Buvry C, Cassagnes L, Tekath M, et al. - Researchers investigated if there exists a link between anti-Ro52 antibodies and ILD in pSS, via this retrospective analysis depending on the presence or absence of anti-Ro52 antibodies in patients with pSS. At the time of diagnosis or during follow-up, chest HRCT was performed on patients (n = 68). The most common pattern of ILD was nonspecific interstitial pneumonia. Following 5 years of follow-up, ILD development was not seen in any patient in the anti-Ro52-negative group. In pSS, the presence of anti-Ro52 antibodies was associated with a higher risk of developing ILD. Follow-up in patients with pSS and anti-Ro52 antibodies must include a clinical screening and pulmonary functional tests with DLCO, and chest HRCT is advised to be included in the presence of a decline in the DLCO or clinical symptoms or inspiratory crackles.